+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Rat pancreas tissue and Mouse pancreas tissue lysates, Primary antibody: P09881(CTRB1 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09881(CTRB1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

Chymotrypsinogen B1 (CTRB1) is a pancreatic protease precursor primarily synthesized in the acinar cells of the pancreas. It is enzymatically inactive until cleaved into its active form, chymotrypsin B, which plays a critical role in digesting dietary proteins in the small intestine. CTRB1 is part of a family of serine proteases, sharing structural homology with other chymotrypsinogens like CTRC and CTRA. Dysregulation of CTRB1 has been implicated in pancreatic disorders, including chronic pancreatitis, pancreatic cancer, and diabetes, making it a biomarker of interest in both research and clinical settings.

CTRB1 antibodies are immunological tools designed to detect and quantify CTRB1 protein expression. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA) to study CTRB1's tissue distribution, expression levels, and involvement in disease mechanisms. Polyclonal and monoclonal CTRB1 antibodies are generated using immunogenic peptide sequences specific to CTRB1. ensuring target specificity. Recent studies also explore CTRB1's interaction with other proteases and its potential role in modulating inflammatory pathways, highlighting its therapeutic relevance. Validation of CTRB1 antibodies includes testing for cross-reactivity with related proteases to confirm specificity, which is critical for accurate experimental outcomes in pancreatic research.